Retraction: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells

Retraction of ‘MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells’ by Guimin Chen et al., RSC Adv., 2019, 9, 21139–21146, DOI: 10.1039/C8RA10224D.

Detalles Bibliográficos
Autor principal: Fisher, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2021
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694687/
https://www.ncbi.nlm.nih.gov/pubmed/35427004
http://dx.doi.org/10.1039/d1ra90049h
_version_ 1784619410144624640
author Fisher, Laura
author_facet Fisher, Laura
author_sort Fisher, Laura
collection PubMed
description Retraction of ‘MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells’ by Guimin Chen et al., RSC Adv., 2019, 9, 21139–21146, DOI: 10.1039/C8RA10224D.
format Online
Article
Text
id pubmed-8694687
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-86946872022-04-13 Retraction: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells Fisher, Laura RSC Adv Chemistry Retraction of ‘MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells’ by Guimin Chen et al., RSC Adv., 2019, 9, 21139–21146, DOI: 10.1039/C8RA10224D. The Royal Society of Chemistry 2021-01-27 /pmc/articles/PMC8694687/ /pubmed/35427004 http://dx.doi.org/10.1039/d1ra90049h Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by/3.0/
spellingShingle Chemistry
Fisher, Laura
Retraction: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells
title Retraction: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells
title_full Retraction: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells
title_fullStr Retraction: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells
title_full_unstemmed Retraction: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells
title_short Retraction: MiR-148a agomir based targeting of c-Met and Her-3 is able to attenuate EGFR-T790M mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells
title_sort retraction: mir-148a agomir based targeting of c-met and her-3 is able to attenuate egfr-t790m mutation driven gefitinib and erlotinib resistance in non-small cell lung cancer cells
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8694687/
https://www.ncbi.nlm.nih.gov/pubmed/35427004
http://dx.doi.org/10.1039/d1ra90049h
work_keys_str_mv AT fisherlaura retractionmir148aagomirbasedtargetingofcmetandher3isabletoattenuateegfrt790mmutationdrivengefitinibanderlotinibresistanceinnonsmallcelllungcancercells

Ejemplares similares